期刊文献+

胃癌患者叶酸代谢通路相关基因的多态性与卡培他滨联合紫杉醇化疗后生存期的关系 被引量:2

Relationship between polymorphisms of related genes in the folic acid metabolic pathway and the survival of gastric cancer patients treated with capecitabine combined with paclitaxel
原文传递
导出
摘要 目的:研究胃癌患者的叶酸代谢通路相关基因和肿瘤相关候选基因的多态性与卡培他滨联合紫杉醇化疗后生存期的关系。方法:选取经病理学确诊的胃癌患者93例,采用卡培他滨联合紫杉醇为主的方案进行化疗。以TaqMan-MGB探针方法进行基因分型,包括肿瘤坏死因子(tumor necrosis factor,TNF)A308G(rs1800629)、亚甲基四氢叶酸还原酶(methylenetetrahydrofolate reductase,MTHFR)C677T(rs1801131)及A1298C(rs1801133)、甲硫氨酸合成酶(methionine synthase,MS或MTR)A2756G(rs1805087)和甲硫氨酸合成还原酶(methionine synthase reductase,MTRR)A66G(rs1801394)基因的分型。比较不同基因型患者在化疗后的中位生存时间(median survival time,MST),以及各种因素对其预后的影响。结果:中位随访时间为29.6个月,93例患者的MST为34.93个月。MTHFR A1298C中携带CA基因型胃癌患者的MST为47.50个月,CC基因型患者的MST为22.91个月;经log-rank检验发现,MTHFR1298C/A基因多态性与患者生存期有边际显著性关系(χ2=3.447,P=0.062)。其他基因型多态性与胃癌患者的生存期无显著相关性。COX回归分析显示,性别、酗酒和手术是胃癌患者化疗后预后的主要影响因素。结论:检测MTHFR1298C/A位点基因多态性可在一定程度上预测卡培他滨联合紫杉醇化疗后胃癌患者的生存情况。 Objective:To investigate the association of polymorphisms of related genes in folic acid metabolic pathway and the tumor candidate genes with the survival of gastric cancer patients treated with capecitabine combined with paclitaxel.Methods:Ninety-three patients with pathological diagnosis of gastric cancer were treated with capecitabine plus paclitaxel-based chemotherapy.The gene polymorphisms of tumor necrosis factor(TNF) A308G(rs1800629),methylenetetrahydrofolate reductase(MTHFR) C677T(rs1801131) and A1298C(rs1801133),methionine synthase(MTR) A2756G(rs1805087) and methionine synthase reductase(MTRR) A66G(rs1801394) were detected by TaqMan-MGB probe typing method.The median survival time(MST) of patients with different genotypes was compared,and the effects of various factors on the prognosis were evaluated.Results:The median follow-up period was 29.6 months.The MST of 93 patients was 34.93 months.The MST of patients with MTHFR 1298CA and 1298CC were 47.50 and 22.91 months,respectively.The log-rank test revealed that the polymorphism of MTHFR 1298C/A had marginally significant correlation with the survival of patients(χ2=3.447,P=0.062),and other gene polymorphisms were not associated with the survivals.The gender,drinking and operation were the major prognostic factors for gastric cancer patients receiving chemotherapy.Conclusion:Detection of MTHFR 1298CA polymorphism may predict the survival of gastric cancer patients receiving chemotherapy of capecitabine combined with paclitaxel.
出处 《肿瘤》 CAS CSCD 北大核心 2011年第5期442-447,共6页 Tumor
基金 上海市卫生局科研课题计划项目(编号:2008135)
关键词 胃肿瘤 5 10-亚甲基四氢叶酸还原酶 多态现象 单核苷酸 抗肿瘤联合化疗方案 预后 紫杉醇 卡培他滨 Stomach neoplasms 5 10-Methylenetetrahydrofolate reductase Polymorphism single nucleotide Antineoplastic combined chemotherapy protocols Prognosis Paclitaxel Capecitabine
  • 相关文献

参考文献26

  • 1周国华.单核苷酸多态性(SNP)与个体化用药[J].中国药学杂志,2004,39(2):152-153. 被引量:3
  • 2高长明,吴建中,刘燕婷,丁建华,李苏平,苏平,胡旭,开海涛,Takezaki Toshiro,Tajima Kazuo.胸苷酸合成酶基因多态和生活习惯及亚甲基四氢叶酸还原酶基因协同作用与胃癌的易感性[J].中华流行病学杂志,2003,24(7):599-603. 被引量:16
  • 3高长明,吴建中,丁建华,刘燕婷,臧宇,李苏平,苏平,胡旭,徐天亮,Takezaki Toshiro,Tajima Kazuo.亚甲基四氢叶酸还原酶基因C677T多态性与胃癌易感性的关系[J].中华流行病学杂志,2002,23(4):289-292. 被引量:26
  • 4黄韵映,黄翠珍,龚五星.药物代谢酶基因多态性与白血病治疗反应及预后相关性的研究新进展[J].肿瘤,2010,30(5):450-454. 被引量:2
  • 5CALBIATTI A L,RUIZ M T,BISELLI-CHICOTE P M,et al.5-Methyltetrahydrofolate-homocysteine methyltransferase gene polymorphism (MTR) and risk of head and neck cancer[J].Braz J Med Biol Res,2010,43(5):445-450.
  • 6PLATEK M E,SHIELDS P C,MARIAN C,et al.Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolate-homocysteine methyltransferase in relation to breast cancer risk[J].Cancer Epidemiol Biomarkers Prev,2009,18(9):2453-2459.
  • 7SHI Q,ZHANG Z,LI C,et al.Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer:a case-control analysis[J].Pharmacogenet Cenomics,2005,15(8):547-555.
  • 8CARZA-CONZALEZ E,BOSQUES-PADILLA F J,EL-OMAR E,et al.Role of the polymorphic IL-1B,IL-1RN and TNF-A genes in distal gastric cancer in Mexico[J].Int J Cancer,2005,114(2):237-241.
  • 9LU W,PAN K,ZHANG L,et al.Genetic polymorphisms of interleukin (IL)-IB,IL-1RN,IL-8,IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese populationLJ].Carcinogenesis,2005,26(3):631-636.
  • 10KOHNE C H,WILS J A,WILKE H J.Developments in the treatment of gastric cancer in Europe[J].Oncology (Williston Park),2000,14(12 Suppl 14):22-25.

二级参考文献83

  • 1沈伟,郑磊贞,陈强,孙美兰.乐沙定为基础的化疗方案治疗晚期胃癌临床研究[J].肿瘤防治杂志,2004,11(4):403-404. 被引量:1
  • 2余慧,金润铭,白燕,林雯.急性淋巴细胞白血病患儿亚甲基四氢叶酸还原酶多态性与氨甲蝶呤毒副反应的研究[J].中华儿科杂志,2005,43(4):302-303. 被引量:26
  • 3张娟,浦跃朴,尹立红,朱方艳,郭吉.基因多态性与成人急性白血病易感性关系的研究[J].肿瘤,2005,25(4):346-350. 被引量:11
  • 4中国消费者协会.2000年第11号消费警示[N].人民日报网络版,2000年9月28日.
  • 5GIOVANNETTI E,UGRASENA D G,SUPRIYADI E,et al.Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia[J].Leuk Res,2008,32(1):19-24.
  • 6ROBIEN K,SCHUBERT M M,CHAY T,et al.Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation[J].Bone Marrow Transplant,2006,37(8):799-800.
  • 7IMANISHI H,OKAMURA N,YAGI M,et al.Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma[J].J Hum Genet,2007,52(2):166-171.
  • 8RUIZ-ARGUELLES G J,COCONI-LINARES L N,GARCES-EISELE J,et al.Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico[J].Hematology,2007,12(5):387-391.
  • 9SHIMASAKI N,MORI T,SAMEJIMA H,et al.Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma[J].J Pediatr Hematol Oncol,2006,28(2):64-68.
  • 10JAZBEC J,KITANOVSKI L,APLENC R,et al.No evidence of association of ethylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia[J].Leuk Lymphoma,2005,46(6):893-897.

共引文献73

同被引文献16

  • 1SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(9): 10-29.
  • 2WU NC, SU SM, LIN TJ, et al. Methylenetetrahyd- rofolate reductase C677T and A1298C? polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer[J]. Anticancer Drugs, 2015, 26(8): 888-893.
  • 3CASSIDY J1, CLARKE S, D[AZ-RUBIO E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results [J]. Br J Cancer, 2011, 105 (1) : 58-64.
  • 4CASSIDY J, CLARKE S, DIAZ-RUBIO E, et al. Randomized phase iii study of capecitabine plusoxaliplatin compared with fluorouracil/fohnic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26 (12): 2006-2012.
  • 5ZHANG C, WANG J, GU H, et al. capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials [J]. Oncol Lett, 2012, 3 (4) : 831-838.
  • 6CASTILLO-FERNANDEZ O, SANTIBANEZ M, BAUZA A, et al. Methylenetetrahydrofolate reductase polymorphism (677 C >T) predicts long time to progression in metastatic colon cancer treated with 5- fluorouracil and folinic acid[J]. Arch Med Res, 2010, 41(6) : 430-435.
  • 7WEISBERG I, TRAN P, CHRISTENSEN B, et al. A second genetic polymorphism in methylenetetrahydrofolate reduetase (blTHFR) associated with decreased enzyme activityIJ]. Mol Genet etab, 1998, 64(3) : 169-172.
  • 8TOFFOLI G, DE MATI'IA E. Pharmacogenetic relevance of MTHFR polymorphisms [J]. Pharmacogenomics, 2008, 9(9) : 1195-1206.
  • 9FANG XY, XU WD, HUANG Q, et al. 5,10- Methylenetetrahydrofolate reductase polymorphisms and colon cancer risk: a meta-analysis [J]. Asian Pac J Cancer Prey, 2014, 15(19) : 8245-8250.
  • 10OZEN F, SEN M, OZDEMIR O. Methylenetetrahydrofolate reductase gene germ-line C677T and A1298C SNPs are associated with colorectal cancer risk in the Turkish population [J]. Asian Pac J Cancer Prey, 2014, 15(18): 7731-7735.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部